Intellia Therapeutics (NTLA) Consolidated Net Income: 2015-2025

Historic Consolidated Net Income for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$104.8 million.

  • Intellia Therapeutics' Consolidated Net Income rose 21.02% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 8.75%. This contributed to the annual value of -$486.5 million for FY2024, which is 4.51% down from last year.
  • Intellia Therapeutics' Consolidated Net Income amounted to -$104.8 million in Q3 2025, which was down 2.11% from -$102.6 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Consolidated Net Income peaked at -$46.2 million during Q1 2021, and registered a low of -$143.7 million during Q1 2022.
  • Moreover, its 3-year median value for Consolidated Net Income was -$118.4 million (2023), whereas its average is -$115.6 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Consolidated Net Income crashed by 211.02% in 2022, and later skyrocketed by 30.43% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Consolidated Net Income (Quarterly) stood at -$79.9 million in 2021, then tumbled by 31.06% to -$104.7 million in 2022, then decreased by 21.67% to -$127.4 million in 2023, then rose by 1.27% to -$125.8 million in 2024, then increased by 21.02% to -$104.8 million in 2025.
  • Its Consolidated Net Income stands at -$104.8 million for Q3 2025, versus -$102.6 million for Q2 2025 and -$112.2 million for Q1 2025.